Discovery of triazines as selective PDE4B versus PDE4D inhibitors

https://doi.org/10.1016/j.bmcl.2014.06.002Get rights and content

Abstract

In this study we report a series of triazine derivatives that are potent inhibitors of PDE4B. We also provide a series of structure activity relationships that demonstrate the triazine core can be used to generate subtype selective inhibitors of PDE4B versus PDE4D. A high resolution co-crystal structure shows that the inhibitors interact with a C-terminal regulatory helix (CR3) locking the enzyme in an inactive ‘closed’ conformation. The results show that the compounds interact with both catalytic domain and CR3 residues. This provides the first structure-based approach to engineer PDE4B-selective inhibitors.

Section snippets

Acknowledgments

This study was funded by the National Institute of Mental Health award 1R43MH091791 to M.E.G.

References and notes (11)

  • M.D. Houslay et al.

    Drug Discovery Today

    (2005)
  • D. Fox et al.

    Cell. Signal.

    (2014)
  • S.L. Jin et al.

    J. Allergy Clin. Immunol.

    (2010)
  • K. Naganuma et al.

    Bioorg. Med. Chem. Lett.

    (2009)
  • R. Gewald et al.

    Bioorg. Med. Chem. Lett.

    (2013)
There are more references available in the full text version of this article.

Cited by (38)

  • Advances in the development of phosphodiesterase-4 inhibitors

    2023, European Journal of Medicinal Chemistry
  • Structure-based optimization of Toddacoumalone as highly potent and selective PDE4 inhibitors with anti-inflammatory effects

    2022, Biochemical Pharmacology
    Citation Excerpt :

    As PDE4A-D were highly conserved in the catalytic domains with sequence similarity of 89% (Fig. 4A) and the key residues interacting with 23a were exactly the same (Fig. 4B), 23a was supposed to have similar inhibitory potencies over PDE4A and PDE4C catalytic domains. The PDE4B or PDE4D isoform selectivity was reported to achieve by interacting with the C-terminal CR3 region or N-terminal UCR2 region [7,49], but the structural alignments of 23a showed no obvious interactions with neither of these regions (Fig. 4C). Therefore, compound 23a is a selective PDE4 inhibitor with no PDE4-subtype selectivity.

  • Pharmacological and Molecular docking studies of new copper (II) complexes of N<sup>2</sup>-Phenyl-N<sup>4</sup>,N<sup>6</sup>-di(thiazol-2-yl)-1,3,5-triazine-2,4,6-triamine

    2022, Journal of Molecular Structure
    Citation Excerpt :

    2-Aminothiazole is served as a viable candidate for the synthesis of many drugs for the treatment of various disorders such as hyperthyroidism, anticonvulsant agents [9–11]. 1,3,5-triazine derivatives are reported to have potent Phosphodiesterase 4 (PDE4) inhibition activity [12,13] which inhibits chronic inflammation. In recent studies the metal complexes of s-triazine derivatives are reported to be good candidate for the discovery of new anti-inflammatory agent [14].

  • Docking based screening and molecular dynamics simulations to identify potential selective PDE4B inhibitor

    2020, Heliyon
    Citation Excerpt :

    Accordingly, pharmacophore-based virtual screening, molecular docking and MD simulations have been applied in this study with the objective to identify a selective PDE4B inhibitor and unravel the crucial amino acids involved in the binding interactions with the inhibitor and its stabilisation in the active site of PDE4B. Forty-three PDE4 inhibitors were selected to constitute the training set compounds based on the inhibitory activity values (IC50) of PDE4B and PDE4D from the reported literature (Supplementary Material-Table S1) (Goto et al., 2014; Hagen et al., 2014; Naganuma et al., 2009). The selected inhibitors have IC50 of PDE4B lower than that of PDE4D thus; they were used for the development of ligand-based (LB) pharmacophore model.

View all citing articles on Scopus
View full text